Simon Dubrey, MD; Lisa Mendes, MD; Martha Skinner, MD; Rodney H. Falk, MD
Patients with AL amyloidosis and congestive heart failure have a very poor prognosis. To date, the recovery of these patients has not been described in detail.
To determine the frequency and characteristics of regression of disease in patients with congestive heart failure due to AL amyloidosis.
Review of patients with systemic AL amyloidosis.
An international referral center for amyloidosis in the United States.
140 patients with congestive heart failure due to AL amyloidosis who were seen between 1983 and 1994.
Functional status, Doppler echocardiography, and objective measurements of disease activity.
3 of 140 patients (2.1%) had marked resolution of congestive heart failure and evidence for remission of disease activity. All 3 had been treated with melphalan.
Melphalan appears to have had a favorable effect in 3 patients with AL amyloidosis and heart failure. The abolition of light chains that was seen in these 3 patients suggests that light-chain toxicity may play a role in the genesis of heart failure in patients with AL amyloidosis.
Dubrey S, Mendes L, Skinner M, et al. Resolution of Heart Failure in Patients with AL Amyloidosis. Ann Intern Med. 1996;125:481–484. doi: https://doi.org/10.7326/0003-4819-125-6-199609150-00009
Download citation file:
Published: Ann Intern Med. 1996;125(6):481-484.
Cardiology, Heart Failure.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use